HFNT Dyspnea Trial, Palliative Care, Finland
ClinicalTrials.gov Studies
Summary
A clinical trial registered on ClinicalTrials.gov is evaluating high-flow nasal therapy (HFNT) as a treatment for dyspnea in patients receiving palliative care. The single-center observational study will recruit approximately 30–40 patients from Hatanpää Palliative Care Ward and Pirkanmaa Hospice in Tampere, Finland. Participants will receive both HFNT and fan therapy (airflow directed toward the face), each lasting 30 minutes, with patient-reported symptom relief as the primary endpoint.
“Patients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
The study registration adds a new clinical trial evaluating HFNT versus fan therapy for dyspnea management in palliative care patients. The trial will enroll approximately 30–40 adult patients at Hatanpää Palliative Care Ward and Pirkanmaa Hospice in Tampere, Finland. Each participant receives both interventions (30 minutes each) with patient-reported benefit and side effects as outcomes.
Healthcare providers and clinical investigators involved in palliative care delivery in Finland who may refer patients to or collaborate with the named sites should be aware of this active enrollment. The study's feasibility data, if positive, could inform broader adoption of HFNT for dyspnea management in hospice settings.
Archived snapshot
Apr 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Management of Dyspnea With High- Flow Nasal Therapy
N/A NCT07552935 Kind: NA Apr 27, 2026
Abstract
Dyspnea in patients with incurable illness is a difficult symptom. Therefore, there is a need to identify new effective treatment modalities. Previous studies suggest that high-flow nasal therapy delivered via a nasal cannula (HFNT = High-Flow Nasal Therapy) may alleviate dyspnea, and similarly that directing airflow toward the face can provide relief. HFNT has been studied very little in hospice settings and on palliative care wards. The aim of this study is to determine whether HFNT is a feasible and effective treatment for relieving dyspnea in patients receiving palliative care.
Patients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland. The target is to recruit approximately 30-40 patients. The inclusion criteria are: age ≥18 years, ability to understand the study and provide informed consent to participate, a palliative treatment approach, and significant dyspnea.
Each patient receives HFNT and fan therapy in which airflow will be directed toward the patient's face. Both treatments will last 30 minutes. Patient symptoms will be asked after the treatments. In addition, patients will be asked to rate the overall benefit they experienced from the intervention and any side effects. The primary endpoint is the relief of dyspnea with HFNT compared with fan therapy.
The study will be conducted in accordance with laws, regulations, and guidelines governing medical research, as well as good scientific practice and research ...
Conditions: Palliative Care, Breathlessness
Interventions: High-flow nasal therapy, Airflow directed to face by a fan
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.